BioCryst to Announce Second Quarter 2017 Financial Results on August 7
July 24 2017 - 6:00AM
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that
its second quarter 2017 financial results will be reported on
Monday, August 7, 2017.
BioCryst will host a conference call and webcast
at 11:00 a.m. Eastern Time to discuss financial results and to
provide an update regarding the Company's clinical development
programs. The call will be led by Jon P. Stonehouse,
President & Chief Executive Officer, Thomas R. Staab II, Senior
Vice President & Chief Financial Officer, and Dr. Bill
Sheridan, Senior Vice President and Chief Medical Officer.
Links to a live audio webcast and replay of the
presentation may be accessed on the BioCryst website events page at
http://investor.shareholder.com/biocryst/events.cfm.
About BioCryst
Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and
develops novel small molecule drugs that block key enzymes involved
in rare diseases. BioCryst has several ongoing development
programs: BCX7353 and other second generation oral inhibitors of
plasma kallikrein for hereditary angioedema, and galidesivir, a
broad spectrum viral RNA polymerase inhibitor that is a potential
treatment for filoviruses. RAPIVAB® (peramivir injection), a viral
neuraminidase inhibitor for the treatment of influenza, is
BioCryst's first approved product and has received regulatory
approval in the U.S., Canada, Japan, Taiwan and Korea.
Post-marketing commitment development activities for RAPIVAB are
ongoing, as well as activities to support regulatory approvals in
other territories. For more information, please visit the Company's
website at www.BioCryst.com.
This press release contains forward-looking statements,
including statements regarding future results and achievements.
These statements involve known and unknown risks, uncertainties and
other factors which may cause our actual results, performance or
achievements to be materially different from any future results,
performances or achievements expressed or implied by the
forward-looking statements. Please refer to the documents BioCryst
files periodically with the SEC and located
at http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
CONTACT: Thomas Staab, BioCryst Pharmaceuticals, +1-919-859-7910
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Apr 2023 to Apr 2024